Spyre Therapeutics announced positive Phase 2 trial results for its investigational therapies SPY001 and SPY002 in ulcerative colitis, showing strong efficacy and safety. The company completed enrollment for its Phase 2 SKYWAY trial in rheumatic diseases, with key data readouts expected in late 2026. Spyre holds $1.1 billion in cash, supporting operations into 2029, and plans pivotal development for SPY072 in rheumatoid arthritis next year. These advances highlight Spyre's potential to deliver improved treatments in immunology with better disease control and dosing convenience.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
Avalanche (AVAX) surged 55% in a week following the launch of Bitwise's Avalanche ETF (BAVA), the first regulated fund offering direct exposure to AVAX tokens with an active staking model. The ETF stakes about 70% of its holdings to generate an estim...
